Company intelligence / Profile preview

MitoCareX Bio

Tel Aviv-Jaffa, Central District, Israel

Ownership: Private
Development stage: Other

Overview

MitoCareX Bio has established robust cloud-based and laboratory screening platforms for identifying small molecule drugs targeting mitochondrial SLC25 carrier proteins in cancer. Lead molecules are progressing towards pre-clinical studies; no clinical or human proof-of-concept data have been reported yet. The company was acquired by N2OFF in 2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

SciSparc

Beyond the preview

Go deeper on MitoCareX Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MitoCareX Bio.

Explore the full profile